Literature DB >> 16984600

Akt expression may predict favorable prognosis in cholangiocarcinoma.

Milind M Javle1, Jihnhee Yu, Thaer Khoury, Krishdeep S Chadha, Krishdeep C Chadha, Renuka V Iyer, Jason Foster, Boris W Kuvshinoff, John F Gibbs, Joseph Geradts, Jennifer D Black, Michael G Brattain.   

Abstract

BACKGROUND: Overexpression of signaling proteins including epidermal growth factor receptor (EGFR), Akt, mitogen activated protein kinase (MAPK) and cyclooxygenase-2 (COX-2) occurs in cholangiocarcinoma cell lines. However, the prognostic value of these markers is unknown. No prior study correlated the expression of these signaling proteins with clinical outcome. Further, co-expression of these proteins has not been reported. Co-expression may reflect cross-talk between signaling pathways. The aim of this clinicopathological study was to investigate the overexpression and co-expression of EGFR and related signaling proteins in cholangiocarcinoma and explore their relationship to clinical outcome.
METHODS: Twenty-four consecutive cases of cholangiocarcinoma treated from 1996 to 2002 at Roswell Park Cancer Institute were included. Immunohistochemical staining of paraffin-embedded tissue sections was performed using antibodies against Akt, p-Akt, MAPK, p-MAPK, COX-2, EGFR and p-EGFR. Two pathologists independently scored the protein expression.
RESULTS: Cyclooxygenase-2, Akt, and p-MAPK were commonly expressed in biliary cancers (100%, 96% and 87% of malignant cells, respectively). EGFR (60%) and p-EGFR (22%) overexpression was also detected. There was a significant association between EGFR and p-EGFR (P = 0.027) and between Akt and p-Akt (P = 0.017) expression in tumor tissue. A noteworthy association was shown between MAPK and p-Akt (P = 0.054). Multivariate analysis using the Cox proportional hazard model identified the use of chemotherapy (hazard ratio [HR] = 0.039, P = 0.0002), radiation (HR = 0.176, P = 0.0441) and Akt expression (HR = 0.139, P = 0.006) as the best predictors of overall prognosis.
CONCLUSION: Epidermal growth factor receptor signaling intermediates are commonly expressed in cholangiocarcinoma. Expression of Akt and use of systemic chemotherapy or radiation may correlate with improved survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16984600     DOI: 10.1111/j.1440-1746.2006.04373.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  21 in total

1.  Frequent activation of mitogen-activated protein kinase relative to Akt in extrahepatic biliary tract cancer.

Authors:  Hiroshige Hori; Tetsuo Ajiki; Yoshiyasu Mita; Hideki Horiuchi; Kenro Hirata; Taku Matsumoto; Haruki Morimoto; Tsunenori Fujita; Yonson Ku; Yoshikazu Kuroda
Journal:  J Gastroenterol       Date:  2007-07-25       Impact factor: 7.527

2.  Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.

Authors:  Supak Yothaisong; Hasaya Dokduang; Anchalee Techasen; Nisana Namwat; Puangrat Yongvanit; Vajarabhongsa Bhudhisawasdi; Anucha Puapairoj; Gregory J Riggins; Watcharin Loilome
Journal:  Tumour Biol       Date:  2013-07-06

3.  Neoalbaconol inhibits cell growth of human cholangiocarcinoma cells by up-regulating PTEN.

Authors:  Guang-Yao Zhou; Chen-Wei Pan; Ling-Xiang Jin; Jian-Jian Zheng; Yong-Xiang Yi
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

4.  Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers.

Authors:  Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Marika Hayashi; Jeffrey A Meyerhardt; Andrew T Chan; Edward Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

5.  A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Hepat Oncol       Date:  2014-01-01

6.  The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma.

Authors:  Joon-Yong Chung; Seung-Mo Hong; Byeong Yeob Choi; Hyungjun Cho; Eunsil Yu; Stephen M Hewitt
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

7.  Integrin-linked kinase cytoplasmic and nuclear expression in laryngeal carcinomas.

Authors:  Anastasios K Goulioumis; Vasiliki Bravou; John Varakis; Panos Goumas; Helen Papadaki
Journal:  Virchows Arch       Date:  2008-09-24       Impact factor: 4.064

8.  Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases.

Authors:  Argun Akcakanat; Aysegul Sahin; Alexandra N Shaye; Marco A Velasco; Funda Meric-Bernstam
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

Review 9.  AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma.

Authors:  K J Schmitz; H Lang; J Wohlschlaeger; G C Sotiropoulos; H Reis; K W Schmid; H A Baba
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

10.  Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.

Authors:  Qinglong Li; Zhulin Yang
Journal:  J Exp Clin Cancer Res       Date:  2009-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.